TL;DR
All systemic medicines for NSCLC are addressed, including precision oncology and biomarker-driven treatments to enhance survival and quality of life.
This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.
Lung cancer is the leading cause of cancer-related deaths worldwide. Over the past decade, immunotherapy, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) or cytotoxic T lymphocyte associated antigen-4 (CTLA-4), has revoluti...
Recent advances in NSCLC with established alterations are summarized, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and emerging targets are discussed, and emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency are discussed.
Cancer is a leading cause of death globally, and traditional therapies including chemotherapy and radiotherapy are often constrained by systemic toxicity and lack of specificity. Thus, targeted therapies are the need of the hour to revolutionize cancer treatment by enhancing specificity and selectivity, and minimizing...
Research directions to make ovarian cancer more susceptible to immunotherapy are moving from empiric treatment to more biologically informed, multimodal approaches aimed at overcoming immune suppression, enhancing antitumor immunity, and personalizing treatment for patients with ovarian cancer.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
